Genmab AS
$ 30.06
-1.76%
11 Feb - close price
- Market Cap 18,849,389,000 USD
- Current Price $ 30.06
- High / Low $ 30.42 / 29.66
- Stock P/E 13.42
- Book Value 93.41
- EPS 2.28
- Next Earning Report 2026-02-17
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.13 %
- ROE 0.29 %
- 52 Week High 35.43
- 52 Week Low 17.23
About
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Analyst Target Price
$37.93
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-12 | 2024-11-06 | 2024-08-08 | 2024-05-02 | 2024-02-14 | 2023-11-07 | 2023-08-03 | 2023-05-10 | 2023-02-22 |
| Reported EPS | 0.65 | 0.54 | 0.31 | 0.84 | 0.29 | 0.32 | 0.29 | 0.14 | 0.46 | 0.3 | 0.05 | 0.13 |
| Estimated EPS | 0.45 | 0.34 | 0.2 | 0.28 | 0.33 | 0.32 | 0.14 | 0.3 | 0.31 | 0.29 | 0.15 | 0.33 |
| Surprise | 0.2 | 0.2 | 0.11 | 0.56 | -0.04 | 0 | 0.15 | -0.16 | 0.15 | 0.01 | -0.1 | -0.2 |
| Surprise Percentage | 44.4444% | 58.8235% | 55% | 200% | -12.1212% | 0% | 107.1429% | -53.3333% | 48.3871% | 3.4483% | -66.6667% | -60.6061% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-17 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.46 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GMAB
2026-02-10 13:28:50
Oppenheimer Asset Management Inc. significantly increased its stake in Genmab A/S (NASDAQ:GMAB) by 24.1% in the third quarter of 2025, purchasing 61,311 additional shares to hold a total of 315,862 shares valued at approximately $9.69 million. Other institutional investors like Orbis Allan Gray Ltd and Arrowstreet Capital also boosted their positions, contributing to institutional ownership levels of about 7.07%. Analysts currently have a "Moderate Buy" consensus rating for Genmab, with an average target price of $39.25, while the stock currently trades around $30.87.
2026-02-10 11:28:50
Genmab A/S (GMAB) is a biotechnology company focused on cancer therapeutics. The company's Darzalex product generated $14.351 billion in worldwide net sales in 2025, from which Genmab receives royalties. Analysts have recently reiterated "Buy" ratings, with BofA expecting significant catalysts in 2026 that could each offer a $2 billion peak sales opportunity, despite a recent price target reduction by H.C. Wainwright due to an Epkinly trial not meeting its primary endpoint.
2026-02-06 12:01:38
Genmab AS (NASDAQ: GMAB) reported strong fourth-quarter results, beating analyst estimates with an EPS of $0.47 against a $0.43 estimate and revenue of $1.06B compared to the $1.03B consensus. The company's stock has shown significant growth, rising 6.57% in the last three months and 63.00% over the last 12 months, with its financial health rated as "great performance" by InvestingPro.
2026-02-06 10:01:38
The article presents Genmab A/S (NASDAQ:GMAB) as a case study for Growth At A Reasonable Price (GARP) investing. It highlights Genmab's strong earnings and revenue growth, along with a fair valuation compared to its industry. The company also demonstrates excellent financial health and profitability, making it an attractive option for investors seeking affordable growth in the biotech sector.
2026-02-05 14:30:39
Genmab has partnered with Anthropic to integrate advanced agentic AI systems, powered by Claude, into its research and clinical development operations. This collaboration aims to streamline data handling, analytical workflows, and regulatory documentation under human supervision, enhancing efficiency and scalability for Genmab's R&D. The goal is to reduce manual workloads, allowing teams to focus on strategic priorities and accelerate the delivery of new treatments to patients.
2026-02-04 17:01:39
Genmab A/S has updated its Articles of Association, effective January 29, 2026, to provide the board with greater flexibility in capital-raising and incentivizing staff. The revisions confirm the company's current share capital and authorize the board to increase share capital, issue warrants, and convertible debt, which could potentially dilute existing shareholders over time. Analysts currently rate GMAB stock as a "Buy" with a $38.00 price target, and TipRanks' AI Analyst has given it an "Outperform" rating due to strong financial performance and strategic initiatives.
